Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis

Successful rechallenge with avelumab in a patient with advanced Merkel cell carcinoma who presented pembrolizumab‐induced myositis

Abstract Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer, associated with high mortality. Immune checkpoint inhibitors (ICIs) have demonstrated long‐lasting efficiency for treating advanced MCC. Despite a good safety profile, ICI remain associated with non‐negligible...

Full description

Bibliographic Details
Main Authors: Clémence Bertold, Laura Troin, Madleen Chassang, Thierry Passeron, Jérôme Doyen, Henri Montaudié, Alexandra Picard‐Gauci
Format: Article
Language:English
Published: Wiley 2023-12-01
Series:JEADV Clinical Practice
Subjects:
immune checkpoint inhibitors
immune‐related adverse events
immunotherapy
metastatic Merkel cell carcinoma
rechallenge
Online Access:https://doi.org/10.1002/jvc2.232

Internet

https://doi.org/10.1002/jvc2.232

Similar Items